Small molecule inhibitors are chemically synthesized organic compounds with a molecular weight of less than 1000, which can smoothly enter cells through a concentration gradient, and inhibit tumor growth by blocking the signal transduction pathway of cancer cells. Targeting the key targets or markers of glucose metabolism reprogramming in the process of cancer has become a research hotspot, and the development of small molecule inhibitors targeting glucose metabolism pathways has become a research hotspot in the field of cancer therapy. Several small-molecule inhibitors targeting metabolic reprogramming in cancer have been approved, and some are still in clinical trials. However, there are few small-molecule drugs targeting the reprogramming of glucose metabolism in cancer. CD BioGlyco can provide customers with high-quality services in all stages of research and development of small molecule inhibitors targeting tumor glucose metabolism.
Table. 1 Small molecule that targets cancer metabolism (Stine ZE, et al., 2022)
CD BioGlyco can provide customized services to help accelerate your small molecule inhibitors drug discovery and development workflow.
CD BioGlyco can provide preclinical CRO services targeting small molecule inhibitors of cancer glucose metabolism reprogramming, including drug discovery, toxicity testing and safety testing. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.